Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Strober

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Drug Safety|April 24, 2019
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
The Journal of Dermatological Treatment|October 5, 2019
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Journal of the American Academy of Dermatology|August 4, 2009
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis FoundationKavita Menon, Abby S Van Voorhees, Bruce F Bebo, et al.
Archives of Dermatology|November 18, 2009
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober, Kavita Menon, Amy McMichael, et al.
Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.
Journal of the American Academy of Dermatology|August 9, 2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasisJashin J Wu, Bruce E Strober, Peter R Hansen, et al.
Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Dermatology and Therapy|May 9, 2024
Brodalumab: 5-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Drug Safety|April 24, 2019
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
The Journal of Dermatological Treatment|October 5, 2019
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.
Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
Journal of the American Academy of Dermatology|August 4, 2009
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis FoundationKavita Menon, Abby S Van Voorhees, Bruce F Bebo, et al.
Archives of Dermatology|November 18, 2009
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober, Kavita Menon, Amy McMichael, et al.
Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.
Journal of the American Academy of Dermatology|August 9, 2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasisJashin J Wu, Bruce E Strober, Peter R Hansen, et al.
Dermatology and Therapy|July 29, 2025
Brodalumab: Seven-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
Dermatology and Therapy|May 9, 2024
Brodalumab: 5-Year US Pharmacovigilance ReportMark G Lebwohl, John Y Koo, April W Armstrong, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Pageof 9